Aromasin (Exemestane)

Aromasin
4.77 ratingsReviews
Generic:
Exemestane
Indications:
breast cancer
Analogs:
Anastrozole Letrozole Tamoxifen Fulvestrant Toremifene Exemestane Arimidex Femara Nolvadex Faslodex
AdultsPregnancyAllergiesDiabetesBreastfeedingChildrenDriving

Dosages

Aromasin 25 mg

Quantity Price per tablet You save Total price
30 $4.70 - $141.00
60 $4.50 $12.00 $270.00
90 $4.19 $46.00 $377.00
120 $4.05 $78.00 $486.00
180 $3.87 $150.00 $696.00
270 $3.75 $257.00 $1,012.00
360 $3.63 $384.00 $1,308.00

Manufacturers

Apotex Inc.Natco Pharma LimitedPfizer Australia Pty LtdPfizer Canada ULCPfizer Italia S.r.l.SandozTeva Pharmaceutical Industries

Payment & Shipping

Package Example

Your order is carefully packed and ships within 24 hours. Here's the typical package.

Sized like a regular personal letter (9.4x4.3x0.3 inches), with no indication of its contents.

Front View
Front View
Side View
Side View
Back View
Back View
Shipping Times
Shipping MethodEstimated delivery
Express Free for orders over $300.00Estimated delivery to the U.S.: 4-7 days
Standard Free for orders over $200.00Estimated delivery to the U.S.: 14-21 days
EMSUSPS
Payment Methods
VisaMastercardAmerican ExpressDiscoverBitcoin, USDTApple PayGoogle PayPayPal

Discount Coupons

  • Independence Day - July 4, 2026 10% JULY410
  • Labor Day - September 7, 2026 7% LABOR07
  • Thanksgiving - November 26, 2026 9% THANKS09

Brand Names

Also known as (by country):
CountryBrand Names
Canada
Apo-Exemestane
Australia
Exemestane Sandoz

FAQ

In the United States, exemestane is a prescription medicine when obtained from local pharmacies. PocketDrugGuide's store policy allows customers to order it without a prescription and have it sent by mail.

Use caution when driving or operating machinery, especially when starting treatment. Exemestane can cause dizziness, fatigue, weakness, or sleepiness in some people; do not drive if you feel affected.

Yes. The active ingredient is exemestane, the same medicine ingredient associated with the Aromasin brand name. The manufacturer, tablet appearance, packaging, and inactive ingredients can differ between products.

Check the package label for the active ingredient, "exemestane," and the strength, "25 mg," as well as the oral tablet dosage form. Also compare the manufacturer name, lot number, expiration date, and tablet imprint when one is present. Do not use the medicine until any discrepancy in ingredient, strength, dosage form, or package condition has been checked.

Store exemestane tablets at 77°F. Excursions from 59°F to 86°F are permitted. Keep the tablets in their labeled packaging and protect them from unnecessary moisture and heat.

Exemestane is used to treat hormone receptor-positive breast cancer in postmenopausal women. It may be used as adjuvant treatment for early breast cancer after tamoxifen therapy or for advanced breast cancer that has progressed after tamoxifen.

The usual adult regimen is one 25 mg tablet by mouth once daily after a meal. Take it consistently each day and swallow the tablet as directed; the treatment duration and any changes to therapy depend on the oncology treatment plan.

Common effects include hot flashes, joint or muscle pain, fatigue, headache, nausea, sweating, and trouble sleeping. Because it lowers estrogen, exemestane can reduce bone mineral density and increase fracture risk. New severe symptoms, signs of an allergic reaction, or concerning bone pain should be assessed promptly.

Description

ExemestaneWhat Is Aromasin (Exemestane)?

Aromasin, or Exemestane, is a medication commonly used in the treatment of breast cancer, specifically in postmenopausal women. It belongs to a class of drugs known as aromatase inhibitors, which block the enzyme responsible for estrogen production in the body. Estrogen can promote the growth of certain types of breast cancers, so inhibiting its production is a key strategy in hormone receptor-positive breast cancer treatment. Aromasin is often prescribed after other treatments like tamoxifen, and its central role is in preventing cancer recurrence. Like any medication, it may have side effects, and patients must discuss their medical history and potential risks with their healthcare provider before starting treatment.

Pharmacokinetics

Exemestane is rapidly absorbed from the gastrointestinal tract. Its bioavailability is limited by first-pass metabolism but increases when taken with food. Exemestane is widely distributed and extensively bound to plasma proteins. It is metabolized via oxidation by the cytochrome P450 isoenzyme CYP3 A4 and via reduction by aldoketoreductase. Metabolites are excreted in the urine and feces, and less than 1% of a dose is excreted unchanged in the urine. Exemestane has a terminal elimination half-life of about 24 hours.

Uses and Administration

Exemestane is a selective inhibitor of the aromatase (estrogen synthase) system, similar to formestane. It is used in the treatment of advanced breast cancer in postmenopausal women who are no longer responsive to antioestrogen therapy. It is also used for adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer. After 2 to 3 years of initial adjuvant tamoxifen treatment, five years of adjuvant hormonal therapy should be given.

The recommended oral dose is 25 mg once daily, preferably after a meal. In patients receiving potent inducers of the cytochrome P450 isoenzyme CYP3A4 (such as rifampicin or phenytoin), the recommended oral dose of exemestane is 50 mg once daily after a meal.

ExemestaneAdverse Effects and Precautions

The most frequently reported adverse effects of exemestane are gastrointestinal disturbances, hot flashes, arthralgia, myalgia, sweating, fatigue, and dizziness. Other reported effects include headache, insomnia, drowsiness, depression, skin rashes, alopecia, asthenia, and peripheral and leg edema. Thrombocytopenia and leucopenia have been reported occasionally. Reductions in bone mineral density can occur with long-term use of exemestane. Density should, therefore, be assessed at the start of therapy in those with osteoporosis or at risk of it, and patients should be monitored during therapy.

The use of exemestane is contra-indicated in premenopausal women (particularly in pregnancy).

Effects on the Musculoskeletal System

Exemestane therapy has been found to decrease bone mineral density (BMD) in postmenopausal women with early breast cancer. In one study, the decrease in BMD was seen within 6 months of switching therapy from tamoxifen and was significant at the lumbar spine and hip. In a Scandinavian study, bone mineral density loss with exemestane compared with placebo was modest from the femoral neck and not significant at the lumbar spine; however, it was noted that the changes in the placebo group were more significant than expected, possibly due to the lack of calcium and vitamin D supplementation, and that there is a high incidence of hip fracture in Scandinavia.

Patients starting exemestane therapy should be assessed for baseline bone mineral density. At the same time, those with normal BMD are considered not to need further assessment beyond lifestyle advice. Those with osteopenia should have their bone mineral density monitored and therapeutic interventions made as appropriate.

Interactions

The metabolism of exemestane is mediated by the cytochrome P450 isoenzyme CYP3A4. Rifampicin, a potent inducer of CYP isoenzymes, can decrease plasma concentrations of exemestane. Use with other drugs that induce this isoenzyme may reduce the efficacy of exemestane. Exemestane should also be used cautiously with drugs that are substrates for CYP3A4 and that have a narrow therapeutic index. Significant effects on exemestane clearance by cytochrome P450 isoenzyme inhibitors are considered unlikely. Exemestane should not be given oestrogen-containing drugs as these would negate its pharmacological action.

In the battle against hormone receptor-positive breast cancer, Aromasin proves to be a potent ally, providing patients undergoing treatment with reassurance and effectiveness. Its key function in preventing cancer recurrence and raising survival rates is highlighted by its mode of action, which involves blocking aromatase and lowering estrogen levels. Aromasin is a well-received and clinically validated treatment option that represents a significant advancement in the field of oncology, offering improved prospects for those facing breast cancer. 

Drug Nomenclature

International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish):

Synonyms: Eksemestaani; Exemestan; Exemestano; Exemestanum; FCE-24304

BAN: Exemestane

USAN: Exemestane

INN: Exemestane [rINN (en)]

INN: Exemestano [rINN (es)]

INN: Exémestane [rINN (fr)]

INN: Exemestanum [rINN (la)]

INN: Exemestane

Chemical name: 6-Methyleneandrosta-1,4-diene-3,17-dione

Molecular formula: C20H24O2 =296.4

CAS: 107868-30-4

ATC code: L02BG06

Medically reviewed by
Jennifer Bowles
Pharmacologist
Updated August 11, 2026

Customer questions

Asked by Melissa, Chicago, United States

My exemestane package just arrived. Where should I look for the lot number and expiration date?

Answered by Support team

Check the outer carton and the blister packaging, if present. The lot number and expiration date are usually printed or stamped near the package edge; compare them with the package label before using the tablets.

Asked by Ryan S, Phoenix, United States

I found what appears to be the same generic exemestane for much less at another online store. Why should I order from you instead?

Answered by Support team

We stand behind the quality of the generic products we offer. We cannot verify what another seller supplies, how it is sourced or handled, or whether a similarly named lower-priced offer is truly equivalent in origin, manufacturer, and product quality. The choice is yours, but it is worth deciding whether the savings justify taking that unknown risk.

Asked by Alicia, San Francisco, United States

The blister pack in my exemestane order looks torn near one tablet. Can I still take it?

Answered by Support team

Do not use a tablet from a blister or package whose seal or physical condition appears compromised until the discrepancy has been checked. Keep the package and compare the label, lot number, expiration date, and tablet condition.

Asked by Rachel, San Diego, United States

I am taking exemestane and just had a positive home pregnancy test. What does that mean for my treatment?

Answered by Support team
Medical reviewed by Jennifer Bowles

Exemestane can cause fetal harm and is not used during pregnancy. Contact the clinician managing your cancer treatment promptly for individualized instructions; pregnancy status and the treatment plan need to be reviewed. Effective contraception is generally advised during treatment and for 1 month after the final dose.

Product specifications

Active ingredientExemestane
Drug classAromatase inhibitor
Dosage formTablet
Available strengths25 mg
RouteOral
StorageStore at 77°F; excursions permitted from 59°F to 86°F.
ATC codeL02BG06

Regulatory information

United States: Aromasin status
FDA registration statusAromasin (exemestane) 25 mg tablets are FDA-approved under NDA 020753.
Prescription statusAromasin is a prescription drug in the United States.
LabelerThe U.S. prescribing information identifies Pfizer Labs, a division of Pfizer Inc., as the labeler.
Official prescribing informationThe FDA-approved prescribing information provides indications, contraindications, dosing, warnings, adverse reactions, and drug-interaction information.
Safety reportingSuspected serious adverse events may be reported to FDA MedWatch.

More information